Standout Papers

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase ... 2009 2026 2014 2020 1.1k
  1. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (2009)
    Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology
  2. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014)
    Marcia S. Brose, Christopher M. Nutting et al. The Lancet

Immediate Impact

3 by Nobel laureates 4 from Science/Nature 68 standout
Sub-graph 1 of 16

Citing Papers

Thyroid Cancer
2024 Standout
Cancer statistics, 2023
2023 Standout
28 intermediate papers

Works of Carol Peña being referenced

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
2014 Standout
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
2009 Standout

Author Peers

Author Last Decade Papers Cites
Carol Peña 867 757 485 898 872 9 2.3k
Annetta Krebs 1849 1941 392 709 405 8 2.7k
Frauke Bentzien 510 657 296 805 241 12 2.0k
Cristiana Lupi 611 1628 363 694 1129 34 2.7k
Katherine Liau 833 1082 436 858 382 36 2.0k
Ronak Shah 295 759 406 681 653 23 1.8k
Josef Brueggen 342 620 378 1819 252 14 2.4k
Jong-Yeon Shin 619 564 518 945 354 25 1.8k
Alex Smith 1032 585 397 626 289 21 2.1k
Joseph T. Spaulding 1502 454 256 406 412 21 2.2k
Mária Dudás 805 643 490 791 201 21 2.0k

All Works

Loading papers...

Rankless by CCL
2026